Compare ONL & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | CGEN |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | United States | Israel |
| Employees | 40 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 125.3M |
| IPO Year | N/A | 2000 |
| Metric | ONL | CGEN |
|---|---|---|
| Price | $2.06 | $1.65 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 284.6K | 271.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.46 | $1.13 |
| 52 Week High | $4.25 | $2.66 |
| Indicator | ONL | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 53.50 |
| Support Level | $1.92 | $1.47 |
| Resistance Level | $2.31 | $1.61 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 26.53 | 72.03 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.